share_log

Oppenheimer Maintains Outperform on Viracta Therapeutics, Maintains $13 Price Target

Moomoo 24/7 ·  Apr 17 08:49

Oppenheimer analyst Hartaj Singh maintains Viracta Therapeutics (NASDAQ:VIRX) with a Outperform and maintains $13 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment